Little Green Pharma
Little Green Pharma has appointed pharmaceutical regulatory executive Beatriz Vicén Banzo to its board as a non-executive director.
Banzo previously served as director of public affairs and quality for pharmaceutical giant Bayer in Spain, responsible for quality assurance, regulatory affairs, pricing and market access across the company’s divisions.
Prior to that she was head of regulatory affairs at global healthcare company Novartis Pharmaceutical for nearly 10 years.
LGP CEO Fleta Solomon said: “I am very excited to welcome Beatriz to the leadership team at Little Green Pharma. Her experience in international pharmaceutical management and regulation is unmatched and will no doubt be a major asset to the company as we continue to expand.
“In particular, she has detailed knowledge of the development requirements for products in European and international markets, as well as experience executing strategies to build leadership positions in the pharmaceutical industry.”
In other news, LGP has signed a German supply agreement with Franfurt-licensed pharmaceutical wholesaler Ilios Santé.
Under the two-year deal, Ilios Santé must purchase minimum annual quantities of a high-THC white-label medicinal cannabis flower product being developed by LGP at its Denmark facilities.
The agreement, which has a value of around A$2 million, may be terminated by LGP if its cost of production exceeds the minimum product purchase price.
Solomon said the partnership “strengthens our share of the medicinal cannabis product market” and “strategically partners us with [Ilios Santé owner] The Bloomwell Group, a European leader in medical cannabis groups operating along the entire value chain”.
Humacology
Humacology is releasing two new oils into the Australia market this week containing minor cannabinoids cannabigerol (CBG) and cannabinol (CBN).
The 3:150:50 THC:CBD:CBG and 3:200:15 THC:CBD:CBN blends retail at A$164 including pharmacy dispensing fees and shipping if ordered via one of the firm’s dispensing partners.
The oil containing CBG has been formulated to boost energy, while the CBN oil is intended to act more as a relaxant. Both contain more than 4% terpenes.
In May, Bod Australia reported promising results from a proof-of-concept study into the safety and efficacy of a CBG dominant cannabis extract and unveiled plans to launch a pharmaceutical-grade CBG product into the Australian and UK prescription markets under its MediCabilis brand.
The Sustainable Nutrition Group
The Sustainable Nutrition Group (TSNG) has extended its voluntary suspension from the ASX, first announced in May, until the end of July as it completes a strategic review.
The move comes after the loss of a strategic customer supply agreement in May and the subsequent resignation of managing director and CEO Neale Joseph.
TSNG said it expects the suspension to remain in place until the earlier of close of trading on July 29, 2022 or when the review is complete.
Creso Pharma
Creso Pharma has signed a heads of agreement with pet care distributor Gotro Global to launch products from its Sierra Sage Herbs subsidiary in Singapore.
Under the agreement, Gotro will market select pet care products from Sierra’s range in Singapore, with a formal agreement planned before the end of August, unless the heads of agreement is extended.
CEO and managing director William Lay said: “This collaboration has grown from a strong alignment on the view that consumers want high quality, healthy, eco-friendly pet care products.
To further underline its Asian ambitions, Creso has also signed a letter of intent with Seoul-based Providence Animal Health Korea (PAHK) to work towards the registration, importation and commercialisation of its Anibidiol products in South Korea.
PAHK supplies pet food and pet health products in South Korea via strong relationships with veterinarians, clinics and animal health stores and established e-commerce channels.
Subject to the registration of Anibidiol products and the execution of a commercialisation agreement between the parties, sales are expected to start in Q1 2023.
Lay added: “Korea is of strategic importance to Creso Pharma, as the country provides another lucrative potential market and may allow the company to further expand into the Asia-Pacific region.”
ECS Botanics
ECS Botanics has completed its first shipment of dried cannabis flower to New Zealand distributor Nubu as part of a four-year supply agreement announced in August 2021.
The strains, cultivated at the firm’s Victoria facility, are registered as flower for inhalation and will be prescribed to patients under Nubu’s Kikuya brand.
ECS said it expects New Zealand to become a strong market for the company in 2022/23.
Managing director Nan-Maree Schoerie added: “This shipment demonstrates ECS’ high-quality products, as New Zealand has one of the highest barriers for entry for imported medicinal cannabis.”
“I am confident that our product will be as well received by New Zealand patients, as it has been by our Australian and other overseas patients.”
Zelira Therapeutics
Zelira’s cannabinoid-based insomnia medication Zenivol has received formal approval from the German regulatory authority BfArM.
The company described the approval as a “necessary and major milestone” for it to enter the German market via its distribution agreement with commercialisation partner Adjupharm.
The approval will expand the availability of Zenivol beyond Australia for the first time.
Cannasouth
Cannasouth has signed a three-year agreement with German importer Weeco Pharma for the supply of cannabis flower from New Zealand into Europe.
Under individual cultivar supply agreements to be negotiated, cannabis flower will be supplied to Weeco from Cannasouth’s cultivation and processing facility in Waikato, New Zealand.
Weeco has first right of refusal for each new cultivar developed by Cannasouth, subject to minimum purchase volumes. The firms have also agreed to work together to develop cultivars to best suit the European market.
Cannasouth said the deal could eventually be worth NZ$12 to 15 million.
It added it will retain sufficient flower to supply the local New Zealand market, enabling its medicinal cannabis products to be verified.
